INTRODUCTION
============

Angiotensin converting enzyme(ACE) is a dipeptidylcarboxypeptidase which catalyzes cleaving dipeptides from C-terminal of various oligopeptides^[@b1-kjim-9-2-67-3],[@b2-kjim-9-2-67-3])^. In vascular endothelium of various organs including lung, it catalyzes conversion of decapeptide angiotensin I to octapeptide angiotensin II and inactivation of bradykinin resulting in elevation of blood pressure^[@b3-kjim-9-2-67-3],[@b4-kjim-9-2-67-3])^. ACE also exists in various organs such as small intestine, kidney, central nervous system and thyroid^[@b5-kjim-9-2-67-3])^. Although it has been suggested that it induces thirst or stimulates the secretion of ADH in central nervous system^[@b6-kjim-9-2-67-3])^ and regulates the glomerular filtration or sodium, water absorption in renal tubular epithelium^[@b7-kjim-9-2-67-3])^, its exact roles in small intestinal epithelium are not known. It has been reported that it participates in sodium and water absorption in small intestine via metabolism of kinin and angiotensin I^[@b8-kjim-9-2-67-3],[@b9-kjim-9-2-67-3])^ and that it also plays some role in digestion of proline-rich proteins^[@b10-kjim-9-2-67-3]--[@b13-kjim-9-2-67-3])^. Many kinds of ACE specific inhibitors are now used widely for the treatment of various types of hypertension and congestive heart failure^[@b14-kjim-9-2-67-3],[@b15-kjim-9-2-67-3])^. Although it has been reported that intestinal ACE was inhibited site-specifically by various ACE inhibitors directly in vitro^[@b16-kjim-9-2-67-3],[@b17-kjim-9-2-67-3])^, it is not clear whether ACE specific activities are also inhibited by long-term ingestion of ACE inihbitors. The aim of this study is to observe the effects of long-term treatment of ACE inihbitors, captopril and enalapril on rat intestinal ACE specific activities.

MATERIALS AND METHODS
=====================

1. Subjects and Drug Administration
-----------------------------------

Thirty adult wistar rats weighing 200g in average were divided into three treatment groups. Rats in the control group were supplied with tap water, captopril group with captopril-containing water(about 25mg/kg/day) and enalapril group with enalapril-containing water (about 12.5mg/kg/day). All the rats were fed with standard rat chows ad libitum for four weeks. Bovine serum albumin, Hippuryl-histidyl-leucine and o-phthalialdehyde were purchased from Sigma(St. Louis, USA) and p-nitrophenyl phosphate from Merk(New Jersey, USA). Captopril and enalapril were kindly provided by Squibb(Seoul, Korea) and Choong-oi Pharmaceuticals(Seoul, Korea) respectively.

2. Preparation of Tissue
------------------------

After four weeks and midnight fasting, all the rats were sacrificed and their small intestines were removed, kept on ice and perfused with cold saline. Removed small intestine was divided equally into three segments. Mucosa was obtained from each segment with slide scraping method and immediately frozen to −20°C.

3. Preparation of Tissue Homogenate
-----------------------------------

Thirty ml of buffer solution (a mixture of 2 mM Tris chloride and 50 mM mannitol(pH 7.0) in 1:1 volume ratio) was added to each gram of stored mucosa which was homogenized with Waring blender for one minute. After adding 0.4M CaCl~2~ to final concentration of 10 mM, the tissue solution was stirred to dissolve and let stand on ice for 20 minutes.

4. Preparation of Brush Border Membrane(BBM)
--------------------------------------------

BBM fraction was extracted from tissue homogenate by minor modification of Kesslers methods^[@b15-kjim-9-2-67-3])^. Briefly, after centrifuging the previously prepared homogenate solution with 3,000×g in 4°C for 15minutes, supernatant was taken and centrifuged again with 27,000×g for 30minutes. After discarding the supernatant, same volume of buffer solution as in preparation of homogenate was added to remnant pellet and homogenized 20 strokes with Potter-Elvehzen homogenizer. After adding 0.4M MgCl~2~ to final concentration of 50 mM, it was centrifuged with 4,000×g in 4°C for 15 minutes and supernatant was taken, centrifuged again with 27,000×g for 30 minutes. After discarding the supernatant, 5ml of phosphate buffered saline(pH 7.4) was added to remnant pellet and mixed well with glass rod and stored in −20°C.

5. Measurement of Protein Levels and Enzyme Specific Activities
---------------------------------------------------------------

Protein concentration was measured by Lowry method^[@b16-kjim-9-2-67-3])^. Alkaline phosphatase specific activity was estimated by Fujita's method^[@b17-kjim-9-2-67-3])^ using 10mM p-nitrophenyl phosphate as substrate. ACE specific activity was measured by minor modification of Cushamn's method^[@b18-kjim-9-2-67-3])^ using Hippuryl-Histidyl-Leucine as substrate. Buffer/substrate solution(pH 8.5) containing 0.0625 M HEPES and 0.375M NaCl. Twenty five *μ*l of distilled water were added to 200*μ*l of previously prepared buffer/substrate solution, mixed well and incubated in 37°C water bath for 30minutes. After 30 minutes, 1.5ml of 0.3M NaOH and 100*μ*l of o-phthalialdehyde solution(0.2% o-phthalaldehyde 2.5mg per 1 ml of methanol) were added to reaction mixture and incubated for 10minutes. After adding 200*μ*l of 0.3M HCl to reaction mixture, it was incubated for 30 minutes until stabilized. Its relative fluorescence was measured using scanning spectrofluorometer (Farrand optical sys-3) with excitation at 365*λ* and emission at 500*λ*. Ten and twenty nmol Histidyl-Leucine was used as standard and the linearity of relative fluorescence between them was confirmed. Protein concentration was measured in *μ*g/10*μ*l solution and enzyme specific activities were expressed in terms of substrate digested in 1 minute per 1 mg protein. ACE specific activity was calculated as follows.

F1/F2×1/30(min)×10×1/2.5×1/protein(*μ*g/10*μ*l)×1,000×(dilution factor)(nmol/min/mg protein)

F1: fluorescence of 25*μ*l of diluted sample solution

F2: fluorescence of 25*μ*l of 10nmol standard solution

6. Statistical Analysis
-----------------------

All measured values were expressed in mean±standard deviation and statistical differences were tested among treatment groups on each segment using nonparametric Kruskal-Wallis test and Mann-Whitney U test.

RESULTS
=======

1. Protein Concentration
------------------------

As protein levels were used as denominators in calculating enzyme specific activities, the levels should be evenly distributed. There was no significant difference among treatment groups in homogenate solution. The result was similar in BBM as shown in [Table 1](#t1-kjim-9-2-67-3){ref-type="table"}.

2. Alkaline Phosphatase Specific Activities
-------------------------------------------

Alkaline phosphatase was used as a marker enzyme because of its abundance in proximal small intestine and stability in intestinal brush border membrane. As expected, its specific activities were highest in the proximal segment and decreased abruptly along the distal segment, and there was no significant difference among treatment groups in each segment. There was also no significant difference among treatment groups in each segment. There was also no significant difference among treatment groups in BBM, but the enzyme specific activities were enriched about 10-foldl in them compared to those of homogenate, suggesting that BBM fraction was prepared well as shown in [Table 2](#t2-kjim-9-2-67-3){ref-type="table"}.

3. ACE Specific Activities in Homogenate
----------------------------------------

ACE specific activities of captopril group were increased in proximal and middle segments but it was not statistically significant. However, those of enalapril group were significantly decreased (p\<0.01) in middle and distal segments as shwon in [Table 3](#t3-kjim-9-2-67-3){ref-type="table"}.

4. ACE Specific Activities in BBM
---------------------------------

ACE specific activities of BBM were about 10-fold higher than those of homogenate in the control group. Those of captopril group were significantly increased(p\<0.01 in proximal, p\<0.05 in middle) compared to those of control group. By contrast, those of enalapril group were significantly lower than those of control group in all three segments as shown in [Table 3](#t3-kjim-9-2-67-3){ref-type="table"}.

DISCUSSION
==========

ACE has been shown to be an important peptidase that plays a role in digestion and assimilation of prolyl peptides^[@b10-kjim-9-2-67-3]--[@b12-kjim-9-2-67-3])^. ACE in brush border membrane prepared from human jejunum obtained during exploratory laparotomy showed its enzyme activity was comparable to those of other intestinal digestive enzymes and it was completely inhibited by ramipril, a potent ACE inhibitor^[@b16-kjim-9-2-67-3])^. Such findings suggest that long-term ingestion of ACE inhibitors as antihypertensive treatment mignt cause some impairments in the function of intestinal ACE in humans. But only few groups have reported the effects of longterm treatment of these inhibitors^[@b22-kjim-9-2-67-3]--[@b24-kjim-9-2-67-3])^. Forsuland et al. reported that serum ACE was increased after 4 weeks treatment with captopril 30mg/kg/day in rats and it reflected the increased activity of pulmonary vascular endothelial ACE, but those of other organs were the same as control group^[@b25-kjim-9-2-67-3])^. However, according to other study in which 2.5mg/kg and 12.5mg/kg body weight of captopril was given to rats for 4 weeks, there was no significant difference in specific activities of ACE between treatment and control group^[@b26-kjim-9-2-67-3])^. Actually, ACE specific activities were slightly higher in the treatment group. But the drawback of this study might be that the enzyme activities were measured only in the homogenate sample and the dose of ACE inhibitor was too small to assess its result. Therefore, the authors revised this study by adding another ACE inhibitor and increasing its dosages. The result of the present study is in accordance with others that intestinal ACE was inhibited by ACE inhibitors in vitro^[@b16-kjim-9-2-67-3],[@b17-kjim-9-2-67-3])^ but the long-term in vivo effects on intestinal ACE specific activities were not in consensus. Our finding that intestinal ACE activities were not decreased, but rather increased by in vitro captopril administration, suggests that there may be a compensatory mechanism for possible suppressed ACE by long-term ACE inhibitor administration in patients. However, discrepancy of this kind was not observed in enalapril administered rats. Several ACE inhibitors which are slightly different in their chemical structure are now in clinical use^[@b14-kjim-9-2-67-3],[@b15-kjim-9-2-67-3])^. Little information is currently available whether there has been any difference in the frequency of the intestinal side effects according to their chemical structure in patients with chronic ACE inhibitor medication because of limited number of case reports^[@b22-kjim-9-2-67-3]--[@b24-kjim-9-2-67-3])^. But our data suggests that the digestion and assimilation of protein rich in prolime such as casein, gliadian and collagen could be inhibited in cases with long-term administration of enalapril. However, in the near future, if such information has accumulated enough for its statistical analysis to be possible, we colud correlate the significance of our finding-the difference of long-term effects of captopril and enalapril-to the real clinical setting.

###### 

Protein Contents of Rat Intestinal Mucosal Homogenate & Brush Border Membrane (*μ*g/10*μ*l)

                          Proximal    Middle      Distal
  ----------------------- ----------- ----------- ----------
  Homogenate                                      
   Control                18.5±2.9    18.8±4.1    17.0±3.8
   Captopril              20.1±2.9    18.7±4.1    16.4±5.8
   Enalapril              22.8±3.6    23.2±1.4    17.8±3.1
  Brush Border Membrane                           
   Control                15.0±2.8    18.7±6.1    16.0±5.4
   Captopril              10.7±2.0    13.0±3.2    11.3±5.0
   Enalapril              22.5±15.7   22.1±10.2   16.1±5.5

Values are mean±S.D., n=10 per group. Control, Captopril & Enalapril groups were supplied with tap water, captopril(25mg/kg/day) & enalapril(12.5 mg/kg/day) respectively for four weeks. There was no statistically significant difference compared with control.

###### 

Rat Intestinal Alkaline Phosphatase Activities in Mucosal Homogenate & Brush Border Membrane (nmol/min/mg protein).

                          Proximal       Middle        Distal
  ----------------------- -------------- ------------- ------------------------------------------------------------
  Homogenate                                           
   Control                134.8± 78.4    59.5± 10.9    54.1± 18.1
   Captopril              138.1± 36.1    73.2± 8.6     69.1± 9.2
   Enalapril              156.4± 57.7    55.3± 7.4     53.8± 9.9
  Brush Border Membrane                                
   Control                1045.2±370.8   434.3±235.6   316.7± 122.6
   Captopril              1397.0±558.1   557.6±131.4   512.1± 153.2[\*](#tfn3-kjim-9-2-67-3){ref-type="table-fn"}
   Enalapril              1049.7±680.6   370.5± 81.4   314.7± 65.8

Values are mean±S.D., n=10 per group, Control, Captopril & Enalapril groups were supplied with tap water, captopril (25mg/kg/day) & enalapril(12.5mg/kg/day) respectively for four weeks.

P\<0.05 compared with control.

###### 

Rat Intestinal Angiotensin Converting Enzyme Activities in Mucosal Homogenate & Brush Border Membrane(nmole/min/mg protein)

                          Proximal                                                     Middle                                                      Distal
  ----------------------- ------------------------------------------------------------ ----------------------------------------------------------- ----------------------------------------------------------
  Homogenate                                                                                                                                       
   Control                15.3± 7.4                                                    14.2± 3.1                                                   5.0± 2.0
   Captopril              22.4± 5.2                                                    16.1± 5.8                                                   5.0± 2.0
   Enalapril              7.4± 3.6                                                     5.7± 1.7[\*\*](#tfn6-kjim-9-2-67-3){ref-type="table-fn"}    2.4± 0.8[\*](#tfn5-kjim-9-2-67-3){ref-type="table-fn"}
  Brush Border Membrane                                                                                                                            
   Control                178.6±64.2                                                   180.3±60.2                                                  48.6±13.1
   Captopril              314.2±72.5[\*\*](#tfn6-kjim-9-2-67-3){ref-type="table-fn"}   281.0±69.8[\*](#tfn5-kjim-9-2-67-3){ref-type="table-fn"}    67.7±21.8
   Enalapril              48.5±27.6[\*\*](#tfn6-kjim-9-2-67-3){ref-type="table-fn"}    70.7±15.6[\*\*](#tfn6-kjim-9-2-67-3){ref-type="table-fn"}   11.6±4.4[\*\*](#tfn6-kjim-9-2-67-3){ref-type="table-fn"}

Values are mean±S.D., n=10 per group. Control, Captopril & Enalapril groups were supplied with tap water, captopril (25mg/kg/day) & enalapril (12.5mg/kg/day) respectively for four weeks.

P\<0.05,

P\<0.01 compared with control.
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